Page last updated: 2024-12-09

2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole is a chemical compound with the molecular formula C14H9N3O3.

Here's a breakdown of its structure and importance:

**Structure:**

* **1,3,4-oxadiazole:** This is the core ring structure, a heterocyclic ring containing one oxygen and two nitrogen atoms.
* **2-(3-nitrophenyl):** This indicates a 3-nitrophenyl group (a benzene ring with a nitro group at the 3rd position) attached to the 2nd position of the oxadiazole ring.
* **5-phenyl:** This indicates a phenyl group (a benzene ring) attached to the 5th position of the oxadiazole ring.

**Importance in Research:**

While the specific compound 2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole might not have widespread applications itself, 1,3,4-oxadiazoles in general, and especially those substituted with aromatic groups, are important in research due to their diverse biological and pharmacological activities.

Here's why:

* **Potential pharmacological activities:** 1,3,4-oxadiazoles have shown promise as:
* **Antibacterial agents:** They can inhibit the growth of bacteria.
* **Antiviral agents:** They can interfere with viral replication.
* **Anticancer agents:** They can inhibit the growth of cancer cells.
* **Anti-inflammatory agents:** They can reduce inflammation.
* **Anticonvulsants:** They can help control seizures.
* **Antidiabetic agents:** They can help regulate blood sugar levels.

* **Versatile building blocks:** The oxadiazole ring can be further modified with various substituents, allowing for the development of libraries of compounds with different properties.
* **Synthetic accessibility:** The synthesis of 1,3,4-oxadiazoles is relatively straightforward, making them suitable for medicinal chemistry studies.

**Specific to 2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole:**

Without specific research data, it's impossible to definitively say why this specific compound might be of interest. However, given its structure, it could be investigated for the following reasons:

* **Exploring the effect of the nitro group:** The nitro group is an electron-withdrawing group, which could influence the compound's biological activity, possibly making it more potent or selective.
* **Investigating the impact of different substitution patterns:** The phenyl group at the 5th position and the nitrophenyl group at the 2nd position might influence the compound's interaction with biological targets.

**Important Note:** To understand the specific importance of this compound, you would need to consult relevant research articles or databases.

Cross-References

ID SourceID
PubMed CID577329
CHEMBL ID1427014
CHEBI ID119852
SCHEMBL ID10245542

Synonyms (20)

Synonym
smr000287045
MLS000709882 ,
CHEBI:119852
AKOS000586392
2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
HMS2685C20
1874-38-0
F1018-0197
SCHEMBL10245542
cid_577329
bdbm63525
2-phenyl-5-(3-nitrophenyl)-1,3,4-oxadiazole (2j)
CHEMBL1427014
2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole #
1,2,4-oxadiazole, 5-(3-nitrophenyl)-3-phenyl-
PPAQPCTUYHOPLY-UHFFFAOYSA-N
Z50148819
Q27207333
2-(3-nitro-phenyl)-5-phenyl-(1,3,4)oxadiazole
CS-0269876
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency15.10140.007215.758889.3584AID588342
Nrf2Homo sapiens (human)Potency4.07100.09208.222223.1093AID624171; AID651593; AID651597
ATAD5 protein, partialHomo sapiens (human)Potency8.69620.004110.890331.5287AID504466; AID504467
Microtubule-associated protein tauHomo sapiens (human)Potency1.25890.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency8.91250.011212.4002100.0000AID1030
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency2.81840.01262.451825.0177AID485313
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency2.23870.00022.621531.4954AID485297
gemininHomo sapiens (human)Potency16.36010.004611.374133.4983AID624296
VprHuman immunodeficiency virus 1Potency35.48131.584919.626463.0957AID651644
survival motor neuron protein isoform dHomo sapiens (human)Potency19.95260.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency3.98110.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)195.00000.160024.4900236.5000AID2382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1801909Proteolytic Activity Assay from Article 10.1016/j.bioorg.2016.05.003: \\2,5-Diaryloxadiazoles and their precursors as novel inhibitors of cathepsins B, H and L.\\2016Bioorganic chemistry, 08, Volume: 672,5-Diaryloxadiazoles and their precursors as novel inhibitors of cathepsins B, H and L.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]